Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07784270 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Study acronym: SELENE 2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Trial sites expanded: 218 → 227 locations · Primary and study completion dates: Aug 9, 2028 to Aug 8, 2028 · Start date changed from estimate of Aug 21, 2026 to Aug 20, 2026 · 1 more Show 4 more changesShow less
    • Trial sites expanded: 218 → 227 locations
    • Primary and study completion dates: Aug 9, 2028 to Aug 8, 2028
    • Start date changed from estimate of Aug 21, 2026 to Aug 20, 2026
    • Eligibility criteria expanded, about 14 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Diabetes
4,286 trials monitored
See 187 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
Type 2 Diabetes
2,100 trials monitored
See 102 trials at risk
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Trial Details
NCT Number NCT07784270
Lead Sponsor AstraZeneca
Conditions Obesity or Overweight, Diabetes Mellitus, Type 2
Enrollment 1,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov